Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Dillard JA, Taft-Benz SA, Knight AC, Anderson EJ, Pressey KD, Parotti B, Martinez SA, Diaz JL, Sarkar S, Madden EA, De la Cruz G, Adams LE, Dinnon KH 3rd, Leist SR, Martinez DR, Schäfer A, Powers JM, Yount BL Jr, Castillo IN, Morales NL, Burdick J, Evangelista MKD, Ralph LM, Pankow NC, Linnertz CL, Lakshmanane P, Montgomery SA, Ferris MT, Baric RS, Baxter VK, Heise MT.
Dillard JA, et al. Among authors: castillo in.
Nat Commun. 2024 May 3;15(1):3738. doi: 10.1038/s41467-024-47450-x.
Nat Commun. 2024.
PMID: 38702297
Free PMC article.